Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05C HYPNOTICS AND SEDATIVES
N05CJ Orexin receptor antagonists
N05CJ02 Lemborexant
D11022 Lemborexant (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Sleep Disorder Agents
Sleep Promoting Agents
Lemborexant
D11022 Lemborexant (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
119 Miscellaneous
1190 Miscellaneous
D11022 Lemborexant (JAN/USAN/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG03225 Orexin receptor antagonist
D11022 Lemborexant
DG03202 Hypnotic
D11022 Lemborexant
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D11022 Lemborexant
DG02925 CYP3A5 substrate
D11022 Lemborexant
Drug classes [BR:br08332]
Neuropsychiatric agent
DG03202 Hypnotic
D11022 Lemborexant
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Orexin
HCRTR
D11022 Lemborexant (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11022
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11022
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11022
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11022